비특이적 엔도뉴클레아제 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 용도별, 최종 용도별, 지역별, 부문별 예측(2026-2033년)

Non-specific Endonucleases Market Summary

The global non-specific endonucleases market size was valued at USD 362.34 million in 2025 and is expected to reach USD 585.19 million by 2033, growing at a CAGR of 6.27% from 2026 to 2033. This growth is primarily fueled by rising R&D investments in molecular biology and biotechnology, where non-specific endonucleases are widely used for nucleic acid clean-up, plasmid production, and removal of host cell DNA during biologics manufacturing.

Regulatory emphasis on high-purity therapeutics and the rapid growth of the recombinant protein and viral vector markets further accelerate adoption. Non-specific endonucleases have become a quiet but essential part of next-generation sequencing (NGS). They make it possible to prepare samples properly, fragment DNA, and build libraries-the building blocks of high-quality sequencing. Ambitious national projects like the UK's 100,000 Genomes Project and France's Genomic Medicine 2025 Plan, the sheer volume of sequencing being done around the world has surged. This surge has created a steady need for enzymatic tools that not only keep up with demand but also deliver cleaner, more reliable data. With governments and research institutions continuing to pour resources into genomics, these enzymes are set to play an even bigger role in ensuring researchers generate accurate results more efficiently than ever before.

The growing use of next-generation sequencing (NGS) has greatly improved diagnostics and precision medicine. Nowadays, scientists and doctors depend on enzymes to deliver accurate and consistent results. Non-specific endonucleases are especially important because they help clean samples by removing unwanted nucleic acids, improving purity, and reducing errors. Their flexibility makes them useful in many areas, including cancer research, immune system studies, and infectious disease testing. As sequencing becomes more affordable and governments continue to support precision medicine, the need for these enzymes is expected to grow.

Worldwide investments in biotechnology and pharmaceuticals are propelling growth in the market. As research developments broaden and drug discovery initiatives speed up, laboratories need scalable and dependable solutions for nucleic acid processing. Non-specific endonucleases address this requirement by aiding in nucleic acid cleanup, minimizing background noise, and guaranteeing reliable performance in assays. Reports suggest that the majority of research laboratories concentrating on oncology, infectious diseases, and immunology are now integrating enzymatic preparation methods into their processes. This underscores the increasing use of these tools in critical research domains.

The market's growth is significantly shaped by the increased emphasis on personalized medicine. Nowadays, treatment planning in oncology, cardiovascular care, and the management of autoimmune diseases heavily relies on genomic profiling. In sensitive applications like liquid biopsies and circulating tumor DNA analysis, non-specific endonucleases play a crucial role in maintaining the integrity of nucleic acid samples. These enzymes contribute to better patient outcomes and increased diagnostic accuracy by delivering cleaner samples and lowering cross-reactivity. Their growing use is indicative of their significance as a pillar of contemporary healthcare, where accuracy and dependability are critical to promoting patient-centered care.

The combination of automation and high-throughput systems is revolutionizing laboratory operations and opening up new avenues for enzymatic solutions. In order to process large sample volumes more quickly and uniformly, non-specific endonucleases are being used more and more in robotic platforms, microfluidic devices, and cartridge-based systems. These developments enable labs to meet the growing demand for genomic testing while lowering manual error and enhancing reproducibility. The market is anticipated to keep growing as high-throughput and point-of-care technologies gain traction globally, as more than half of mid-to-large testing facilities in North America and Europe have already implemented enzyme-assisted automation.

Global Non-specific Endonucleases Market Report Segmentation

This report forecasts revenue growth at the global, regional and country levels and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global non-specific endonucleases market report on the basis of product, application, end use, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Recombinant Non-Specific Endonucleases
• Natural Source Enzymes
• Engineered/Modified Variants
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Biopharmaceutical Production
  • Monoclonal Antibodies (mAbs)
  • Recombinant Proteins
  • Biosimilars
• Cell & Gene Therapy
  • AAV, Lentivirus, Oncolytic Viruses
  • CAR-T and TCR Therapies
• Vaccine Manufacturing
  • mRNA Vaccines
  • Viral Vector Vaccines
• Diagnostics & Research
  • Molecular Biology
  • RNA Analysis & Sequencing Workflows
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Biopharmaceutical & Biotechnology Companies
• Contract Development and Manufacturing Organizations (CDMOs/CMOs)
• Academic & Research Institutions
• Diagnostic Laboratories
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
  • 1.2.1. Product Segment
  • 1.2.2. Application Segment
  • 1.2.3. End-use Segment
• 1.3. Information analysis
  • 1.3.1. Market formulation & data visualization
• 1.4. Data validation & publishing
• 1.5. Information Procurement
  • 1.5.1. Primary Research
• 1.6. Information or Data Analysis
• 1.7. Market Formulation & Validation
• 1.8. Market Model
• 1.9. Total Market: CAGR Calculation
• 1.10. Objectives
  • 1.10.1. Objective 1
  • 1.10.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Insights Landscape

Chapter 3. Global Non-specific Endonucleases Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Expansion of NGS & genomics applications
    • 3.2.1.2. Rising biotech & pharma R&D investment
    • 3.2.1.3. Clinical adoption and personalized medicine
    • 3.2.1.4. Automation & high-throughput workflows
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Technological Evolution Reducing Enzyme Reliance
  • 3.2.3. Market opportunity analysis
• 3.3. Global Non-specific Endonucleases Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis

Chapter 4. Global Non-specific Endonucleases Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Non-specific Endonucleases Market Product Movement Analysis
• 4.3. Global Non-specific Endonucleases Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
• 4.4. Recombinant Non-Specific Endonucleases
  • 4.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 4.5. Natural Source Enzymes
  • 4.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 4.6. Engineered/Modified Variants
  • 4.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Global Non-specific Endonucleases Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Non-specific Endonucleases Market Application Movement Analysis
• 5.3. Global Non-specific Endonucleases Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 5.4. Biopharmaceutical Production
  • 5.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.4.2. Monoclonal Antibodies (mAbs)
    • 5.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.4.3. Recombinant Proteins
    • 5.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.4.4. Biosimilars
    • 5.4.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 5.5. Cell & Gene Therapy
  • 5.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.5.2. AAV, Lentivirus, Oncolytic Viruses
    • 5.5.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.5.3. CAR-T and TCR Therapies
    • 5.5.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 5.6. Vaccine Manufacturing
  • 5.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.6.2. mRNA Vaccines
    • 5.6.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.6.3. Viral Vector Vaccines
    • 5.6.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 5.7. Diagnostics & Research
  • 5.7.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.7.2. Molecular Biology
    • 5.7.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.7.3. RNA Analysis & Sequencing Workflows
    • 5.7.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 5.8. Others
  • 5.8.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Global Non-specific Endonucleases Market: End-use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Non-specific Endonucleases Market End-use Movement Analysis
  • 6.2.1. Global Non-specific Endonucleases Market Size & Trend Analysis, by End-use, 2021 to 2033 (USD Million)
• 6.3. Biopharmaceutical & Biotechnology Companies
  • 6.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 6.4. Contract Development and Manufacturing Organizations (CDMOs/CMOs)
  • 6.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 6.5. Academic & Research Institutions
  • 6.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 6.6. Diagnostic Laboratories
  • 6.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 6.7. Others
  • 6.7.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Non-specific Endonucleases Market: Regional Estimates & Trend Analysis

• 7.1. Regional Dashboard
• 7.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 7.3. North America
  • 7.3.1. U.S.
    • 7.3.1.1. Key country dynamics
    • 7.3.1.2. Regulatory framework/ reimbursement structure
    • 7.3.1.3. Competitive scenario
    • 7.3.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.3.2. Canada
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework/ reimbursement structure
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.3.3. Mexico
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Regulatory framework/ reimbursement structure
    • 7.3.3.3. Competitive scenario
    • 7.3.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/ reimbursement structure
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/ reimbursement structure
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.6. Norway
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework/ reimbursement structure
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework/ reimbursement structure
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework/ reimbursement structure
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.3. India
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.4. Australia
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.2. Argentina
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company/Competition Categorization
• 8.2. Strategy Mapping
• 8.3. Company Market Share Analysis, 2025
• 8.4. List of Key Certification Providers/Scheme Owners
• 8.5. Company Profiles/Listing
  • 8.5.1. F. Hoffmann-La Roche Ltd
    • 8.5.1.1. Company overview
    • 8.5.1.2. Financial performance
    • 8.5.1.3. Product benchmarking
    • 8.5.1.4. Strategic initiatives
  • 8.5.2. Kerry Group plc(c-LEcta)
    • 8.5.2.1. Company overview
    • 8.5.2.2. Financial performance
    • 8.5.2.3. Product benchmarking
    • 8.5.2.4. Strategic initiatives
  • 8.5.3. GenScript Biotech
    • 8.5.3.1. Company overview
    • 8.5.3.2. Financial performance
    • 8.5.3.3. Product benchmarking
    • 8.5.3.4. Strategic initiatives
  • 8.5.4. Beyotime Biotechnology
    • 8.5.4.1. Company overview
    • 8.5.4.2. Financial performance
    • 8.5.4.3. Product benchmarking
    • 8.5.4.4. Strategic initiatives
  • 8.5.5. Vazyme International LLC.
    • 8.5.5.1. Company overview
    • 8.5.5.2. Financial performance
    • 8.5.5.3. Product benchmarking
    • 8.5.5.4. Strategic initiatives
  • 8.5.6. Takara Bio
    • 8.5.6.1. Company overview
    • 8.5.6.2. Financial performance
    • 8.5.6.3. Product benchmarking
    • 8.5.6.4. Strategic initiatives
  • 8.5.7. Promega Corporation
    • 8.5.7.1. Company overview
    • 8.5.7.2. Financial performance
    • 8.5.7.3. Product benchmarking
    • 8.5.7.4. Strategic initiatives
  • 8.5.8. Bio-Techne
    • 8.5.8.1. Company overview
    • 8.5.8.2. Financial performance
    • 8.5.8.3. Product benchmarking
    • 8.5.8.4. Strategic initiatives
  • 8.5.9. ACROBiosystems
    • 8.5.9.1. Company overview
    • 8.5.9.2. Financial performance
    • 8.5.9.3. Product benchmarking
    • 8.5.9.4. Strategic initiatives
  • 8.5.10. MinneBio
    • 8.5.10.1. Company overview
    • 8.5.10.2. Financial performance
    • 8.5.10.3. Product benchmarking
    • 8.5.10.4. Strategic initiatives
  • 8.5.11. New England Biolabs
    • 8.5.11.1. Company overview
    • 8.5.11.2. Financial performance
    • 8.5.11.3. Product benchmarking
    • 8.5.11.4. Strategic initiatives
  • 8.5.12. KACTUS
    • 8.5.12.1. Company overview
    • 8.5.12.2. Financial performance
    • 8.5.12.3. Product benchmarking
    • 8.5.12.4. Strategic initiatives
  • 8.5.13. ArcticZymes Technologies
    • 8.5.13.1. Company overview
    • 8.5.13.2. Financial performance
    • 8.5.13.3. Product benchmarking
    • 8.5.13.4. Strategic initiatives
  • 8.5.14. Worthington Biochemical Corporation
    • 8.5.14.1. Company overview
    • 8.5.14.2. Financial performance
    • 8.5.14.3. Product benchmarking
    • 8.5.14.4. Strategic initiatives
  • 8.5.15. Thermo Fisher Scientific Inc.
    • 8.5.15.1. Company overview
    • 8.5.15.2. Financial performance
    • 8.5.15.3. Product benchmarking
    • 8.5.15.4. Strategic initiatives
  • 8.5.16. RayBiotech, Inc.
    • 8.5.16.1. Company overview
    • 8.5.16.2. Financial performance
    • 8.5.16.3. Product benchmarking
    • 8.5.16.4. Strategic initiatives
  • 8.5.17. TransGen Biotech Co., Ltd
    • 8.5.17.1. Company overview
    • 8.5.17.2. Financial performance
    • 8.5.17.3. Product benchmarking
    • 8.5.17.4. Strategic initiatives
  • 8.5.18. Merck
    • 8.5.18.1. Company overview
    • 8.5.18.2. Financial performance
    • 8.5.18.3. Product benchmarking
    • 8.5.18.4. Strategic initiatives